We use cookies to improve your experience on our Website. We need cookies to continuously improve the services, to enable certain features and when embedding services or content of third parties, such as video player. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:

Only cookies permitted that are required for the basic functionality of our websites.
Permit cookies that help us to analyse the page views and user behavior on our websites. We only use this information for improving our services.
Permit embedded content and cookies from third party providers. This setting enables the full use of our web services (e.g. displaying videos).
Please find more information in our privacy statement.

There you may also change your settings later.

News

DZD scientist among the winners of the Sanofi iAward

Dr. Daniel Markgraf from DZD partner Deutsches Diabetes-Zentrum is one of the winners of the newly created iAward from Sanofi. His work on non-alcoholic fatty liver is part of the selected projects that Sanofi is supporting with its new program in Europe. The aim is to support the establishment of new early research approaches that bring innovative academic research rapidly into the clinical phase and have the potential to offer significant improvements for patients.

Prize winner Dr. Daniel Markgraf and DZD Managing Director Dr. Astrid Glaser. Source: Franck Parisot

The three-year program is set up to invest a total of up to 6 million euros in funding innovative research projects across academic centers in France and Germany. Corresponding institutions from other European countries are expected to join in future years. This year, nineteen academic projects selected by an Academic and Sanofi Joint Steering Committee, among 190 dossiers submitted.

The Sanofi iAwards program seeks to promote potential scientific breakthroughs, especially through the exchange of knowledge between Sanofi and top academic scientific teams. It will fund and nurture selected academic projects for one year, with the potential to lead to further collaborations. The aim is to accelerate the research and development process and address patients’ needs more quickly. These efforts combine new learnings from academic institutions on the biological mechanisms of diseases, and Sanofi’s drug discovery and development capabilities.

“We are very excited with the iAwards initiative launched in Europe, a unique industry–academic partnership designed to enable a new type of healthcare innovation,” said Jochen Maas, Head of R&D Germany Hub and acting Head of Diabetes Research Therapeutic Area, Sanofi. “Europe is a core region in the Sanofi R&D organization and represents almost 50 percent of our global operations. The academic institutes in France and Germany have a critical place in the worldwide scientific community as well. Through deep and networked collaboration, we aim to ensure that the best knowledge and creativity is gathered to develop novel solutions and improve people’s lives.”